Abstract
Drug repositioning is an important component of therapeutic stratification in the precision medicine paradigm. Molecular profiling and more sophisticated analysis of longitudinal clinical data are refining definitions of human diseases, creating needs and opportunities to re-target or reposition approved drugs for alternative indications. Drug repositioning studies have demonstrated success in complex diseases requiring improved therapeutic interventions as well as orphan diseases without any known treatments. An increasing collection of available computational and experimental methods that leverage molecular and clinical data enable diverse drug repositioning strategies. Integration of translational bioinformatics resources, statistical methods, chemoinformatics tools and experimental techniques (including medicinal chemistry techniques) can enable the rapid application of drug repositioning on an increasingly broad scale. Efficient tools are now available for systematic drug-repositioning methods using large repositories of compounds with biological activities. Medicinal chemists along with other translational researchers can play a key role in various aspects of drug repositioning. In this review article, we briefly summarize the history of drug repositioning, explain concepts behind drug repositioning methods, discuss recent computational and experimental advances and highlight available open access resources for effective drug repositioning investigations. We also discuss recent approaches in utilizing electronic health record for outcome assessment of drug repositioning and future avenues of drug repositioning in the light of targeting disease comorbidities, underserved patient communities, individualized medicine and socioeconomic impact.
Keywords: Individualized medicine, Drug repositioning, Network analysis, Translational bioinformatics, Disease comorbidity, Orphan disease, Biomedical data mining.
Current Topics in Medicinal Chemistry
Title:Computational and Experimental Advances in Drug Repositioning for Accelerated Therapeutic Stratification
Volume: 15 Issue: 1
Author(s): Khader Shameer, Ben Readhead and Joel T. Dudley
Affiliation:
Keywords: Individualized medicine, Drug repositioning, Network analysis, Translational bioinformatics, Disease comorbidity, Orphan disease, Biomedical data mining.
Abstract: Drug repositioning is an important component of therapeutic stratification in the precision medicine paradigm. Molecular profiling and more sophisticated analysis of longitudinal clinical data are refining definitions of human diseases, creating needs and opportunities to re-target or reposition approved drugs for alternative indications. Drug repositioning studies have demonstrated success in complex diseases requiring improved therapeutic interventions as well as orphan diseases without any known treatments. An increasing collection of available computational and experimental methods that leverage molecular and clinical data enable diverse drug repositioning strategies. Integration of translational bioinformatics resources, statistical methods, chemoinformatics tools and experimental techniques (including medicinal chemistry techniques) can enable the rapid application of drug repositioning on an increasingly broad scale. Efficient tools are now available for systematic drug-repositioning methods using large repositories of compounds with biological activities. Medicinal chemists along with other translational researchers can play a key role in various aspects of drug repositioning. In this review article, we briefly summarize the history of drug repositioning, explain concepts behind drug repositioning methods, discuss recent computational and experimental advances and highlight available open access resources for effective drug repositioning investigations. We also discuss recent approaches in utilizing electronic health record for outcome assessment of drug repositioning and future avenues of drug repositioning in the light of targeting disease comorbidities, underserved patient communities, individualized medicine and socioeconomic impact.
Export Options
About this article
Cite this article as:
Shameer Khader, Readhead Ben and T. Dudley Joel, Computational and Experimental Advances in Drug Repositioning for Accelerated Therapeutic Stratification, Current Topics in Medicinal Chemistry 2015; 15 (1) . https://dx.doi.org/10.2174/1568026615666150112103510
DOI https://dx.doi.org/10.2174/1568026615666150112103510 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer’s
Disease
Current Drug Research Reviews Overlapping Ligand Specificity of P-Glycoprotein and Serum α1-Acid Glycoprotein:Evidences and Potential Implications
Current Drug Metabolism Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Opinion Paper: Pharmacogenomics Testing for Type B Adverse Drug Reactions to Anti- Infective Drugs: The Example of Hypersensitivity to Abacavir
Recent Patents on Anti-Infective Drug Discovery Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for Ocular Drug Delivery
Pharmaceutical Nanotechnology 7-aa Peptide Mimic from HVR1 of HCV Protects Hepatic Injury in Rats by Reduced Expression of Key Pro-Inflammatory Factors
Inflammation & Allergy - Drug Targets (Discontinued) Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Toll-like Receptor as a Molecular Link between Metabolic Syndrome and Inflammation: A Review
Current Drug Targets Novel Therapeutic Approaches and Treatment Targets for Psoriatic Arthritis
Current Pharmaceutical Biotechnology Down-regulation of MiR-138-5p Protects Chondrocytes ATDC5 and CHON-001 from IL-1 β-induced Inflammation <I>Via</I> Up-regulating SOX9
Current Pharmaceutical Design MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism Dysfunction of Glutamate Receptors in Microglia May Cause Neurodegeneration
Current Alzheimer Research Mesenchymal Cells are a Promising -But Still Unsatisfying- Anti- Inflammatory Therapeutic Strategy for Osteoarthritis: A Narrative Review
Current Rheumatology Reviews TLR3 and TLR4 But not TLR2 are Involved in Vogt-Koyanagi- Harada Disease by Triggering Proinflammatory Cytokines Production Through Promoting the Production of Mitochondrial Reactive Oxygen Species
Current Molecular Medicine Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice
Current Molecular Medicine A 13-Immune Gene Set Signature for Prediction of Colon Cancer Prognosis
Combinatorial Chemistry & High Throughput Screening Interstitial Lung Disease in Systemic Lupus Erythematosus, Sjogren’s Syndrome, and Mixed Connective Tissue Disease
Current Respiratory Medicine Reviews Adipokines and Myokines: A Pivotal Role in Metabolic and Cardiovascular Disorders
Current Medicinal Chemistry